Livtencity

Chemical Namemaribavir
Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
SystemImmune
CompanyTakeda
Approval Year2021

Indication

  • For the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Livtencity (maribavir) Prescribing Information.2021Takeda Pharmaceuticals America Inc., Lexington, MA